Cost of new cholesterol drugs in spotlight
New York
EXPRESS Scripts Holding Co said on Wednesday that two costly new cholesterol fighters will not be "budget busters" for its clients and that most prescriptions for the potent drugs have been rejected because patients did not meet required medical criteria.
"We're seeing a lot of patients who either don't qualify or their physicians are not providing (needed) information," said Everett Neville, a vice-president of Express Scripts, the largest pharmacy benefit manager in the United States.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO